FAIRFIELD, Conn., Oct. 9, 2002 (PRIMEZONE) -- Competitive Technologies, Inc. (AMEX:CTT) announced today that Dr. Isadore Rosenfeld, host of Fox News Live Weekend's Sunday Housecall (www.foxnews.com), called for his listening audience to ask their personal doctor to administer a homocysteine test as part of their routine check-up. Dr. Rosenfeld noted that a high homocysteine level reading could mean that the patient was vulnerable for heart attack, stroke or Alzheimer's disease. He also noted that if high, the homocysteine level can be reduced by your doctor recommending an oral combination of folic acid, and Vitamins B12 and B6.
In addition to hosting Sunday Housecall, Dr. Rosenfeld is an attending physician at New York Hospital and Memorial Sloan Kettering Cancer Center, and is the Rossi Distinguished Professor of Clinical Medicine at New York Hospital Weill Cornell Medical Center. He is recognized as a leading and effective proponent of the medical enlightenment of the American public.
John B. Nano, President and CEO of CTT said, "This is yet another step forward in reinforcing the need to include homocysteine testing in the annual physical exam regimen as an integral diagnostic tool in preventive medicine. Creating public awareness is part of CTT's announced accelerated program to increase knowledge about homocysteine testing which is helpful to the health of the general public."
CTT has licensed the patent covering performance of assays for homocysteine. The patent is derived from discoveries made by CTT's clients Drs. Robert Allen and Sally Stabler from the University of Colorado and the late Dr. John Lindenbaum from Columbia University.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is customer-focused on recognizing and understanding the needs of the market and transforming those wishes into commercially viable technology. CTT is a global leader in identifying, developing and commercializing innovative life sciences, physical sciences, digital technologies and electronics, and nanotechnologies. CTT's specialized expertise and experience make it a valuable partner to assist technology-rich universities, inventors and companies, of all sizes, to maximize the value of their intellectual assets. Visit CTT's website: http://www.competitivetech.net
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in this document other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws and are not guarantees of future performance. These statements involve risks and uncertainties, including those set forth in Item 1 of the Company's most recent Form 10-K and in CTT's other filings with the SEC, and are subject to change at any time. The Company's actual results could differ materially from these forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statement.